Entera Bio Ltd. — Third Quarter 2026 Earnings Summary

Entera Bio Ltd. reported a net loss of $15.6 million for the third quarter ended September 30, 2026, driven primarily by a $7.5 million non-cash fair value remeasurement of pre-funded warrants. The company raised approximately $275 million in a private placement in July 2026, bringing its total cash and cash equivalents to $265.9 million to fund its Phase 3 registrational program for EB613. Clinical preparations for the EB613 Phase 3 osteoporosis study are advancing, with the first site activation expected in late 2026 and topline results anticipated in the second half of 2028. Additionally, Entera expanded its leadership team with new senior executives and board members while continuing IND-enabling activities for its hypoparathyroidism candidate, EB612, in collaboration with OPKO Health.